Despite its promising anti-tumor immune capacity, IL-15 has been shown to exhibit a short half-life and high doses were required to achieve biological responses in vivo [9, 10], hence resulting in clinical toxicities and limited anti-tumor responses in patients [8]. Here, IL15 is linked to neoplasm.